GlaxoSmithKline: Alzheimer Disease trials

The registry lists 34 Alzheimer Disease studies with GlaxoSmithKline as lead sponsor. 2 are open to participants now and 10 have results posted.

Phase 1 14Phase 2 11Phase 3 7Phase 4 1No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in FinlandRecruitingNCT07502560Phase 4
• Open-label Extension Study in Participants With Early Alzheimer's DiseaseRecruitingNCT07105709Phase 2
• A Phase 2a Study to Evaluate the Effect of Rilapladib (SB-659032) in Alzheimer's DiseaseCompletedNCT01428453Phase 2Results posted
• A Study of SB-742457, Added to Donepezil for the Treatment of Mild-to-moderate Alzheimer's DiseaseCompletedNCT00710684Phase 2Results posted
• Study of SB-742457 or Donepezil Versus Placebo in Subjects With Mild-to-moderate Alzheimer's DiseaseCompletedNCT00708552Phase 2Results posted
• Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate AlzheimersTerminatedNCT00550420Phase 3Results posted
• Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate AlzheimersTerminatedNCT00490568Phase 3Results posted
• Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00428090Phase 3Results posted
• Open-Label Extension Assessing Long-Term Safety Of Rosiglitazone In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00381238Phase 2Results posted
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00348309Not applicableResults posted
• Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's DiseaseCompletedNCT00348140Phase 3Results posted
• Brain Imaging Study Of Rosiglitazone Efficacy And Safety In Alzheimer's DiseaseCompletedNCT00265148Phase 2Results posted
• Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's DiseaseTerminatedNCT06079190Phase 2
• Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy VolunteersWithdrawnNCT02130661Phase 1
• GSK2647544 RD, DDI in Healthy Young and Elderly VolunteersTerminatedNCT01978327Phase 1
• A Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F GSK2647544 in Healthy Subjects to Determine Its Ability to Cross the Blood-brain-barrier.TerminatedNCT01924858Phase 1
• Effects of Triglycerides on Age-Related Cognitive Function Decline in Older SubjectsCompletedNCT01702480Phase 1
• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single, Oral Escalating Doses of GSK2647544 in Healthy VolunteersCompletedNCT01702467Phase 1
• Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease PatientCompletedNCT01424436Phase 1
• Study to Evaluate the Efficacy and Safety of GSK239512 in Alzheimer's DiseaseCompletedNCT01009255Phase 2
• Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan StudyCompletedNCT00937846Phase 1
• QTc Study of Rosi XR in Healthy VolunteersWithdrawnNCT00884533Phase 1
• PK, Dose Proportionality, Food Effect And Repeat Dose Study Of Rosiglitazone XR In Healthy VolunteersCompletedNCT00733785Phase 1
• Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)CompletedNCT00688207Phase 1
• Bridging Study With GSK239512 In Patients With Mild To Moderate Alzheimer's DiseaseCompletedNCT00675090Phase 1
• A Study To Assess The Pharmacokinetics Of SB-742457 Formulated As A Capsule And A Tablet In Healthy Elderly Volunteers.CompletedNCT00551772Phase 1
• A Study To Demonstrate The Bioequivalence Of Rosiglitazone XR (BRL-049653) 8mgs XR Manufactured At Two Different Sites.CompletedNCT00468897Phase 1
• A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's DiseaseCompletedNCT00459550Phase 1
• SB-742457 And Donepezil In Alzheimer's DiseaseCompletedNCT00348192Phase 2
• Effects Of Rosiglitazone (Extended Release Tablets) On Cerebral Glucose Utilisation And Cognition Alzheimers DiseaseTerminatedNCT00334568Phase 2
• Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00314912Phase 3
• A Dose Ranging Study To Investigate The Efficacy And Safety Of SB-742457 In Alzheimer's DiseaseCompletedNCT00224497Phase 2
• European Study of 3APS in Mild to Moderate Alzheimer's Disease PatientsStatus unknownNCT00217763Phase 3
• Evaluation of 3APS in Patients With Mild to Moderate Alzheimer's DiseaseStatus unknownNCT00088673Phase 3